The modest EPS and revenue beat combined with maintained guidance supports a constructive view. The aggressive share repurchase program ($348M in Q2) continues to drive EPS accretion. Monitor the Q3 earnings call for any impact from the new Term Loan B-2 on interest expense and leverage, and for updates on normalized treatment growth trends.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 5 $187.61entry
- T+1 · 3mo ago −4.07%α −3.91% · $179.97
- T+5 · 3mo ago −3.26%α −3.61% · $181.50
- T+20 · 3mo ago −4.68%α −4.08% · $178.83
- T+60 · 19d ago +3.04%α +3.10% · $193.31
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
DaVita reported Q2 2026 diluted EPS of $4.02 on consolidated revenues of $3.554B. The EPS beat the Street consensus of $4.01 by a marginal 0.25%, while revenue exceeded the $3.49B estimate by 1.8%. The company maintained its full-year 2026 guidance for adjusted operating income ($2.15B-$2.25B) and adjusted diluted EPS ($14.10-$15.20), signaling confidence in operational momentum despite a slight sequential decline in revenue per treatment.
Key Financial Metrics
Key Facts
- Q2 2026 diluted EPS of $4.02 vs consensus $4.01 (beat by 0.25%)
- Q2 2026 consolidated revenues of $3.554B vs consensus $3.49B (beat by 1.8%)
- Revenue grew 5.2% YoY from $3.380B in Q2 2025
- Operating income of $579M (16.3% margin) vs $538M (15.9%) in Q2 2025
- Full-year 2026 guidance maintained: adjusted operating income $2.15B-$2.25B, adjusted diluted EPS $14.10-$15.20
- Repurchased 2.2M shares for $348M in Q2; additional 0.2M shares for $37M post-quarter
- Incurred $500M incremental Term Loan B-2 tranche in June 2026
Financial Impact
Q2 EPS beat by $0.01 (0.25%) and revenue beat by $64M (1.8%) vs consensus; guidance unchanged
Risk Factors
- Slight sequential decline in revenue per treatment ($415.87 vs $417.59 in Q1 2026)
- Leverage ratio increased to 3.37x from 3.34x in Q1 2026 due to new debt
- Dependence on commercial payor mix and potential downward pressure on rates
- Normalized non-acquired treatment growth remains low at 0.3% YoY
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000927066-26-000105 |
| Document: dva-20260804.htm | 0000927066-26-000105 |
| Document: 0000927066-26-000105-index-headers.html | 0000927066-26-000105 |
| Document: 0000927066-26-000105-index.html | 0000927066-26-000105 |
| Document: 0000927066-26-000105.txt | 0000927066-26-000105 |
| 8-K Data (Synthetic) | 0000927066-26-000105 |
Track record
9 reports on DVA
The track record builds as more bullish or bearish reports settle.
Filters
- Oct 29, 202618d ago 8-K Mixed 5/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $187.50 Now $174.22 −7.08% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Neutral 2/10 Entry $183.64 Now $174.22 −5.13% settles Jan 21
- Aug 4, 202614w ago 8-K Bullish 6/10 Viewing Entry $187.61 to $193.31 Now $174.22 −7.14% ▲ +3.04% +3.10% vs SPY
- Jun 15, 202622w ago Court Ruling Neutral 1/10 Entry $208.98 to $181.55 Now $174.22 −16.63% ▼ −13.13% −14.99% vs SPY
- Jun 8, 202623w ago 8-K Mixed 5/10 Entry $198.19 to $178.83 Now $174.22 −12.09% ▼ −9.77% −13.58% vs SPY
- May 18, 202626w ago Insider Cluster Neutral 3/10 Entry $194.38 to $179.17 Now $174.22 −10.37% ▼ −7.82% −13.84% vs SPY
- May 13, 202626w ago Insider Cluster Bearish 6/10 Entry $192.30 to $183.48 Now $174.22 +9.40% ▲ +4.59% +7.91% vs SPY
- May 5, 202627w ago 8-K Bullish 8/10 Entry $191.76 to $238.86 Now $174.22 −9.15% ▲ +24.56% +23.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers